SCHEMBL30658005

SCHEMBL30658005

Cc1cc2nnc(-c3ccccc3O)cc2n1C1[C@H]2CNC[C@@H]12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PBRM1 Q86U86 15/20 0.38
▸ SMARCA2 P51531 14/20 0.38
▸ SMARCA4 P51532 14/20 0.38
▸ NR1I2 O75469 10/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ NR1H2 P55055 4/20 0.35
▸ NR1H3 Q13133 3/20 0.35
▸ USP2 O75604 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26653951 1.00 PBRM1 (0.38) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26801645 1.00 PBRM1 (0.38) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26654173 0.82 PBRM1 (0.38) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL30658026 0.78 SMARCA2 (0.50) PBRM1SMARCA2SMARCA4BRD4
SCHEMBL26654073 0.74 PBRM1 (0.36) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26653822 0.74 PDE10A (0.42) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL25207807 0.71 PBRM1 (0.41) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26653968 0.70 IKBKB (0.39) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26654149 0.70 IKBKB (0.39) PBRM1SMARCA2SMARCA4NR1I2BRD4
SCHEMBL26654141 0.70 IKBKB (0.39) PBRM1SMARCA2SMARCA4NR1I2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
EP-4522279-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220134-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302832-A1 PYRAZINE DERIVATIVES AND USES THEREOF BRCA1, VHL, SF3B5 PBRM1 7/4885SMARCA2 77/4885SMARCA4 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback